logo

For the Inventor, By the Inventor

Tokyo, Japan

Michio Kojima

USPTO Granted Patents = 11

Average Co-Inventor Count = 6.9

ph-index = 4

Forward Citations = 32(Granted Patents)


Location History:

  • Tokyo, JA (1976 - 1978)
  • Tokyo, JP (1979 - 1983)

Company Filing History:

goldMedal11 out of 382 
 
Meiji Seika Kaisha, Ltd.
 patents

Years Active: 1976-1983

Loading Chart...
11 patents (USPTO):Explore Patents
1. 4404218 - Antibiotic SF-2103A substance and process for production thereof (1983-09-13),
2. 4396603 - Novel antibiotic SF-2107 series substance and process for preparing the (1983-08-02),
3. 4376778 - Antibiotic substances and processes for production thereof (1983-03-15),
4. 4242327 - Antibiotic SF-2052 substance and production and use thereof (1980-12-30),
5. 4209509 - Substance SF-1739 derivatives, process for preparing the same and (1980-06-24),
6. 4202886 - Antibiotic SF-1942 substance and process for production of the same (1980-05-13),
7. 4169140 - Antibiotics SF-1771 substance and SF-1771-B substance as well as the (1979-09-25),
8. 4160026 - Antibiotics SF-1130-x.sub.1 and -x.sub.2 substances and production and (1979-07-03),
9. 4076588 - Antibiotic SF-1623 substance and the production thereof (1978-02-28),
10. 4010155 - Antibiotic SF-1623 substance (1977-03-01),
11. 3974035 - Process for preparing a cephamycin type antibiotic substance (1976-08-10),

Title: Michio Kojima: Innovator in Antibiotic Development

Introduction

Michio Kojima is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of antibiotic research, holding a total of 11 patents. His work focuses on developing novel substances that exhibit antibacterial properties, which are crucial for pharmaceuticals and other applications.

Latest Patents

Kojima's latest patents include the Antibiotic SF-2103A substance and the process for its production. This patent describes an antibiotic SF-2103A substance or a salt thereof, along with a process that involves cultivating a strain that produces this antibiotic in a nutrient medium and recovering the desired substance from the culture broth. Another notable patent is for the novel antibiotic SF-2107 series substance, which consists of Substance SF-2107 A-1, Substance SF-2107 B, and/or Substance SF-2107 C. Each of these substances exhibits antibacterial activity against both gram-positive and gram-negative bacteria, making them useful for pharmaceuticals, bactericides, and disinfectants.

Career Highlights

Kojima is currently employed at Meiji Seika Kaisha, Ltd., where he continues to innovate in the field of antibiotic development. His work has been instrumental in advancing the understanding and application of antibiotics in medical science.

Collaborations

Some of his notable coworkers include Takashi Shomura and Hiroshi Watanabe, who have collaborated with him on various projects related to antibiotic research.

Conclusion

Michio Kojima's contributions to antibiotic development have made a significant impact in the field of pharmaceuticals. His innovative patents and ongoing research continue to pave the way for new treatments against bacterial infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…